Loading
The 2021 update of the projection that pancreatic cancer will become the second leading cause of cancer death in the United States, now dated to 2040 with about 46,000 deaths a year, as deaths from breast, prostate and bowel cancer fall.
Rahib, Wehner, Matrisian and Nead combined SEER delay-adjusted incidence rates, US Census population projections (2016) and average annual percentage changes in incidence and death rates to estimate cancer incidence and deaths to 2040. They estimated that breast (364,000 cases), melanoma (219,000), lung (208,000) and colorectal (147,000) would be the commonest cancers, with prostate falling to fourteenth (66,000). Lung cancer (63,000 deaths) would remain the leading cause of cancer death, with pancreatic cancer (46,000) and liver and intrahepatic bile duct cancer (41,000) surpassing colorectal cancer (34,000) to become second and third; breast cancer (30,000) would fall to fifth.
Pancreatic cancer's share of cancer deaths rises because it is standing still while others improve; the 2014 projection to 2030 already made it the second cause of cancer death in the UK's peer countries, and this is the funding argument charities on both sides of the Atlantic use.
Shares JAMA, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pancreatic-evidence.
Shares Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares JAMA, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.
Shares Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag pancreatic-evidence.